These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35604050)

  • 1. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
    Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccine-induced urticarial vasculitis.
    Dash S; Behera B; Sethy M; Mishra J; Garg S
    Dermatol Ther; 2021 Sep; 34(5):e15093. PubMed ID: 34369046
    [No Abstract]   [Full Text] [Related]  

  • 3. Urticarial vasculitis after COVID-19 vaccination: A case report and literature review.
    Ono H; Yamaguchi R; Shimizu A
    Dermatol Ther; 2022 Aug; 35(8):e15613. PubMed ID: 35652448
    [No Abstract]   [Full Text] [Related]  

  • 4. [Leukocytoclastic vasculitis and acute renal failure following inactivated SARS-CoV-2 vaccine].
    Missoum S; Lahmar M; Khellaf G
    Nephrol Ther; 2022 Jul; 18(4):287-290. PubMed ID: 35074300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytoclastic vasculitis flare following the COVID-19 vaccine.
    Cohen SR; Prussick L; Kahn JS; Gao DX; Radfar A; Rosmarin D
    Int J Dermatol; 2021 Aug; 60(8):1032-1033. PubMed ID: 33928638
    [No Abstract]   [Full Text] [Related]  

  • 6. Urticarial vasculitis following mRNA anti-COVID-19 vaccine.
    Nazzaro G; Maronese CA
    Dermatol Ther; 2022 Mar; 35(3):e15282. PubMed ID: 34931406
    [No Abstract]   [Full Text] [Related]  

  • 7. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
    Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
    Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
    [No Abstract]   [Full Text] [Related]  

  • 8. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review.
    Abdelmaksoud A; Wollina U; Temiz SA; Hasan A
    Dermatol Ther; 2022 Jun; 35(6):e15458. PubMed ID: 35306713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEVERE LEUKOCYTOCLASTIC VASCULITIS AFTER COVID-19 VACCINATION - CAUSE OR COINCIDENCE? CASE REPORT AND LITERATURE REVIEW.
    Wollina U; Schönlebe J; Kodim A; Hansel G
    Georgian Med News; 2022 Mar; (324):134-139. PubMed ID: 35417874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of Leukocytoclastic Vasculitis Following SARS-COV-2 Vaccination.
    Ball-Burack MR; Kosowsky JM
    J Emerg Med; 2022 Aug; 63(2):e62-e65. PubMed ID: 35690533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.
    Wolfson AR; Freeman EE; Blumenthal KG
    JAMA; 2022 May; 327(17):1702-1703. PubMed ID: 35420647
    [No Abstract]   [Full Text] [Related]  

  • 12. Extensive cutaneous leukocytoclastic vasculitis after Sinopharm vaccine: Case report and review of the literature.
    Azzazi Y; Abdelkader HA; Khedr H; El-Komy MHM
    J Cutan Pathol; 2022 Aug; 49(8):736-742. PubMed ID: 35355299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous vasculitis due to COVID-19 vaccination.
    Gázquez Aguilera EM; Rodríguez García M; Cantón Yebra MT
    Med Clin (Barc); 2022 May; 158(10):493-494. PubMed ID: 34895746
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine.
    Zeng G
    Lancet Microbe; 2022 Aug; 3(8):e561. PubMed ID: 35659883
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.
    Iwamura N; Eguchi K; Koga T; Tsutsumi K; Araki T; Aramaki T; Takatani A; Terada K; Ueki Y
    Immunol Med; 2023 Jun; 46(2):97-107. PubMed ID: 36950829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
    Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
    Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
    [No Abstract]   [Full Text] [Related]  

  • 17. [Delayed acute urticaria after the third vaccine against SARS-CoV-2].
    Gimeno Castillo J; Garrapiz Borderías I
    Semergen; 2022 Sep; 48(6):437-438. PubMed ID: 35527184
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired hemophilia A with SARS-CoV-2 mRNA vaccine: first case from Pakistan.
    Rashid A; Khan Z; Alam J
    Scand J Clin Lab Invest; 2022 Sep; 82(5):432-434. PubMed ID: 35767232
    [No Abstract]   [Full Text] [Related]  

  • 20. Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance.
    Kharkar V; Vishwanath T; Mahajan S; Joshi R; Gole P
    Clin Exp Dermatol; 2021 Dec; 46(8):1596-1597. PubMed ID: 34115904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.